Changelog
What changed, and when.
Every change to the data, in plain language, by version. Every printed report names the version it used.
Current datav2026.11.09c700 records · updated 2026-11-09
v2026.11.09c, 2026-11-09
- AddedTen interleukin-blocking biologics: secukinumab (Cosentyx), ixekizumab (Taltz), bimekizumab (Bimzelx), brodalumab (Siliq), guselkumab (Tremfya), risankizumab (Skyrizi), tildrakizumab (Ilumya), mirikizumab (Omvoh), ustekinumab (Stelara and biosimilars) and tocilizumab (Actemra and biosimilars).
- AddedSix JAK-family inhibitors: tofacitinib (Xeljanz), upadacitinib (Rinvoq), baricitinib (Olumiant), abrocitinib (Cibinqo), ritlecitinib (Litfulo) and deucravacitinib (Sotyktu).
- AddedOther immune-modulating medications: apremilast (Otezla), abatacept (Orencia), rituximab (Rituxan and biosimilars), vedolizumab (Entyvio), ozanimod (Zeposia) and etrasimod (Velsipity).
- AddedSearch groups: IL-17 and IL-23 blockers; JAK inhibitors.
v2026.11.09b, 2026-11-09
- AddedFour TNF-blocking biologics: certolizumab pegol (Cimzia), infliximab (Remicade and biosimilars, including Zymfentra), etanercept (Enbrel) and golimumab (Simponi, Simponi Aria).
- ChangedAdalimumab: US biosimilar brand names added for search (Amjevita, Cyltezo, Hyrimoz, Hadlima, Yusimry, Idacio, Yuflyma, Abrilada, Simlandi).
- AddedSearch group: TNF blockers.
v2026.11.09, 2026-11-09
- ChangedRecords no longer show a “Clinical contraindication” line. It recorded only whether a medication's own label contraindicates use with a drug class that includes psilocybin, which is true for 2 of 674 records; “None listed” on the other 672 could be misread as a finding about the combination. The field remains in the data download, with its description corrected to say it is a label check only.
- EvidencePhenelzine and tranylcypromine: the interaction text now states that each label contraindicates use with serotonergic drugs, a class that includes psilocybin.
v2026.11.02, 2026-11-02
- AddedFour medications approved by the FDA in 2026: milsaperidone (Bysanti), centanafadine (Simtriyo), oveporexton (Orzeyful) and tavapadon (Juvmo).
- AddedFive more medications approved by the FDA in 2026: baxdrostat (Baxfendy), enlicitide (Lipfendra), insulin efsitora (Onswik), insulin icodec (Awiqli) and icotrokinra (Icotyde).
v2026.10.25b, 2026-10-25
- FlagsProchlorperazine: 5-HT2A blocking added as possible, from receptor-binding data (PDSP Ki database).
- SourcesEntries without psilocybin data now cite the two systematic reviews of psychedelic drug interactions for the absence of a reported interaction, and mark the product-label citation that supports the Detail text.
v2026.10.25, 2026-10-25
- OregonRule 333-333-5050 (3)(d) and (5)(d) now quote the current official text: the question covers prescription medications, non-prescription medication and nutritional supplements, and (5)(d) includes the written medication plan. Oregon, Colorado and New Mexico rule text checked 2026-10-24.
- FlagsSedating flag added to risperidone, paliperidone, aripiprazole, brexpiprazole, cariprazine and fosphenytoin, from their labels' somnolence warnings. Psychiatric-reactions flag added to dosulepin and lofepramine (antidepressant suicidality warning). Zuclopenthixol: 5-HT2A blocking added as possible. Paroxetine: QT flag marked possible, because its label says a causal link has not been established.
- FlagsMAO-inhibition definition: lab studies disagree on how much MAO clears psilocin, so the definition now says it may help clear it.
- EvidenceClass overviews: escitalopram reduced psilocybin's rise in blood pressure, not heart rate (Becker 2022); the MAO-inhibitor statement on serotonin toxicity now cites the two reports directly, and the 1968 study's participants are described as patients abstinent from alcohol; valproate inhibits one glucuronidation enzyme (UGT2B7); haloperidol did not prevent psilocybin's effects; clearer wording on Colorado's antipsychotic rule on the sleep page.
- EvidenceTranylcypromine: the 1968 study's 9 participants were patients abstinent from alcohol. Isocarboxazid: its label contraindicates SSRIs but, unlike phenelzine's and tranylcypromine's, not serotonergic drugs as a class.
- SourcesPapers named in the text are now listed in the sources (Bonson & Murphy 1996, Tap 2025, Barnett 2024). The figure for psilocybin excreted as 4-HIAA is marked as cited in Thomann 2024.
- ChangedContraindication definition: a label that states use with a class including psilocybin is contraindicated counts wherever in the label it says so. No record changes level.
- ChangedPlainer wording: "stacks with" now reads "adds to"; lion's mane uses the standard no-data sentence; topical minoxidil's label warnings reworded. Intranasal oxytocin no longer lists the injection's FDA-approved uses as its own.
- FixedRecord history for orforglipron, insulin glargine–lixisenatide, aspirin and hydromorphone shows the right release. Duplicate search names removed. Fentanyl: the IV half-life note now reads about 7 hours (range 3–12), as the label states.
v2026.10.24, 2026-10-24
- ChangedDisclaimer shortened to one sentence on what Psilodex presents; its meaning is unchanged.
- ChangedOpioid property definition split into separate sentences; no change in meaning.
- ChangedState rules page: Colorado program named as the Office of Natural Medicine Licensure (Division of Professions and Occupations); Oregon status reads "Rules in effect", as Colorado does.
v2026.10.23b, 2026-10-23
- ChangedRemaining entries that said "no known interaction" now say the medication has not been studied with psilocybin and that no mechanism linking them has been described.
- ChangedEntries without psilocybin data now open with one standard sentence.
- ChangedIbuprofen and naproxen: removed the qualifier "with occasional use".
- ChangedPlainer summary lines for amiodarone and lithium.
- SourcesSource notes on review articles cited for absence of a reported interaction now read "no reported interaction".
- ChangedState rules page: wording on what Psilodex summarizes, and dates in year-month-day form.
- New MexicoState rules page: the public hearing on proposed rule 7.35.3 NMAC was held 2026-10-02; the rule is still not adopted.
v2026.10.23, 2026-10-23
- AddedState rules page: links to the official Colorado, New Mexico and Oregon rules, notices and statutes, with recent changes and the date each state was last checked.
v2026.10.18, 2026-10-18
- AddedClass pages: short cited overviews for SNRI antidepressants, MAO inhibitors, tricyclic antidepressants, opioids and sleep medications.
v2026.10.14b, 2026-10-14
- ColoradoPsychotropic entries that no Colorado provision names now note rule 2.2(A)(9): facilitators must tell prospective participants in writing that anyone taking a psychotropic medication identified as a risk factor on the safety screen must meet one of the 2.2(A)(7) conditions. Status is unchanged (not named).
- EvidenceTranylcypromine: the 1968 placebo-controlled study is described more fully (9 people, 2 days of tranylcypromine, psilocybin 20 mg; randomization and blinding not reported; no blood pressure figures reported).
- SourcesClass overviews: statements previously cited to a pharmacology textbook now cite the relevant FDA prescribing information.
v2026.10.14, 2026-10-14
- AddedClass pages: short cited overviews for SSRI antidepressants, antidepressants, stimulants and ADHD medications, mood stabilizers, antipsychotics and benzodiazepines.
- OregonLithium orotate moves from Named to Unsettled. Oregon’s Client Information Form asks about “the prescription drug Lithium”; whether that covers non-prescription lithium orotate supplements has not been addressed.
- ColoradoLithium and antipsychotic entries: the opening summary no longer reads “a facilitator can serve…”. It now says rules 2.2(A)(6) and 2.2(A)(7) both address these medications and that the rule text does not state how the two fit together. The rule quotations are unchanged.
- EvidenceBenzodiazepines: removed the unsourced statement that they may make psilocybin feel weaker. Entries now note that the one benzodiazepine studied with psilocybin (midazolam) left the experience conscious while partly impairing memory of it (Nicholas 2024); diazepam also cites published safety guidelines (Johnson 2008).
- EvidenceSSRIs, SNRIs and vortioxetine: “serotonin syndrome risk appears low” now cites its source (Sarparast 2022) and adds that unlikely is not impossible. Citalopram, escitalopram and sertraline now state that stopping suddenly after regular use can cause withdrawal.
- SourcesBarnett 2024 case report: the phenelzine exposure is described as one 3 g dose; the later hypertensive emergency now notes that emergency catheterization found no significant cardiac abnormalities, and the amphetamine entry names tranylcypromine and the authors’ attribution to phenylethylamine in the mushrooms.
v2026.10.13b, 2026-10-13
- ChangedNew Mexico rule column: entries for atypical antipsychotics, SSRIs and SNRIs, tricyclic antidepressants, trazodone, vilazodone, vortioxetine, mirtazapine, buspirone, benzodiazepines, cannabis, alcohol, GLP-1 agonists and lamotrigine now note the medication-interaction working list adopted by a Department of Health advisory committee on 2026-03-17. The list is not part of the proposed rule, so these entries stay Pending.
v2026.10.13, 2026-10-13
- AddedPublic launch: 665 medications and substances.
- ChangedColorado rule column: promethazine and its cough syrups, metoclopramide (Reglan), amoxapine and lithium orotate move from Named to Unsettled. The rule names lithium and “antipsychotic medications” without defining the term, so whether it covers these is unsettled; each entry explains why the question exists. Cobenfy (xanomeline–trospium), approved for schizophrenia, stays Named.
v2026.10.05c, 2026-10-05
- ChangedColorado rule column: Cobenfy, promethazine and its cough syrups, amoxapine and metoclopramide (Reglan) move from Unsettled to Named. The rule does not define "antipsychotic medications", so these entries show it as covering them and explain why the question exists; the regulator has not addressed it. Lithium orotate supplements are shown the same way under the Colorado and Oregon lithium provisions.
- AddedNew entry: norgestrel (Opill), the over-the-counter progestin-only birth control pill.
- ChangedSummaries now use "Also" throughout to introduce effects of the medicine itself, replacing "Separately".
- ChangedAbout 50 summaries reworded: entries without psilocybin data now say plainly that the combination is untested, and long sentences were split for easier reading. Facts and sources are unchanged.
- FixedSearch: "7-OH", "Drisdol", "M30s" and "pressed pills" now lead only to the entry they name.
v2026.10.05b, 2026-10-05
- Changed33 more entries without psilocybin data now open with "Not studied with psilocybin" instead of "No known interaction".
- AddedEach entry page lists the release notes that mention it, under Record history.
v2026.10.05, 2026-10-05
- ChangedColorado rule column: named entries now open with a one-line summary: a facilitator can serve someone taking lithium or an antipsychotic only after a licensed medical or behavioral health provider has referred them, cleared them, or done a risk review with them. The exact rule text follows.
- ChangedProchlorperazine (Compazine) moves from Unsettled to Named under Colorado's antipsychotic rule: it is a phenothiazine antipsychotic FDA-approved for schizophrenia.
- ChangedClearer wording on about 320 entries: sentences about effects that matter on the day (sedation, breathing, blood pressure, seizures, serotonin syndrome, heart rhythm) now begin with "Also" rather than "Separately", and entries without psilocybin data open with "Not studied with psilocybin".
v2026.10.04, 2026-10-04
- AddedTwo new sections on some entries: "Effect duration", where the effect outlasts the half-life (for example MAO inhibitors, depot injections, clopidogrel, long-acting insulin), and "Other safety", for important warnings unrelated to psilocybin (for example nitrates with sildenafil, boxed warnings).
- ChangedAbout 40 more entries updated from sources found for open audit items, including discontinuation flags for several antipsychotics and new half-lives for mescaline and prochlorperazine.
- ChangedState status tiles keep showing whether a rule names the medication itself; rules that name a condition the medicine is commonly used for are listed under Conditions.
- AddedNew entries: Aleve PM, Tylenol PM, Dymista (azelastine and fluticasone), Promethazine DM, Xultophy (insulin degludec and liraglutide), BiDil (isosorbide dinitrate and hydralazine) and Recorlev (levoketoconazole).
- ChangedOregon rule text is now quoted word for word from OAR 333-333-5050, with each question (section 3) shown next to its consequence (section 5); pregnancy and history-of-harm questions added.
- ChangedHalf-lives added or re-sourced for duloxetine, tacrolimus, MDA, primidone (phenobarbital metabolite) and the norgestrel pill; condition information corrected on about 20 entries.
- ChangedHalf-lives added for about 27 more entries, including insulin glargine, nitrofurantoin, desiccated thyroid, kratom, harmala alkaloids, berberine, heroin, salvinorin A, 5-MeO-DMT, 7-OH, xylazine and medetomidine, and per-ingredient values for combination products.
- ChangedCorrected the description of the haloperidol study (Vollenweider 1998) on antipsychotic and anti-nausea entries: dopamine blockade did not prevent psilocybin's effects, and it increased anxiety.
- ChangedCorrected the phenelzine case report: no noticeable psychedelic effects at two doses (Barnett 2024). The "psilocybin data" label now counts only data on the combination with psilocybin or another classic psychedelic.
- ChangedColorado rule 2.2(A)(6), (7) and (9) now quoted word for word, including the licensing, documentation, safety-plan and written-consent requirements.
- ChangedMAO-inhibitor entries now lead with the human data (reduced or absent psychedelic response with phenelzine and isocarboxazid; blood-pressure rise with tranylcypromine), with the theoretical effect on psilocin clearance second. Selegiline, rasagiline, linezolid and methylene blue are now relative rather than absolute contraindications.
- ChangedColorado rule column: for Cobenfy, prochlorperazine (Compazine), promethazine and its cough syrups, amoxapine and metoclopramide (Reglan), the entry now explains why it is unclear whether Colorado's antipsychotic rule covers them. Cobenfy moves from Named to Unsettled, and metoclopramide from Not named to Unsettled.
- ChangedPsilocybin data: bupropion now shows survey data (fewer reports of weaker effects than with SSRIs or SNRIs); nortriptyline, valproate, propranolol, zolpidem and amphetamine salts now cite a published case report; seven antidepressants cite a DMT trial; eight tricyclic-type entries now show "None known" because the LSD study they cite did not include them.
- ChangedColorado rule column: antipsychotic entries now quote the rule term without adding wording that is not in the rule. Metoclopramide lists its injection uses.
- FixedHalf-lives for 19 entries now cite the specific FDA label; three values that no FDA label states (triamterene, diphenhydramine, dextromethorphan alone) were removed.
- FixedFentanyl patch: serum levels fall by about half in 20–27 hours after removal (FDA label), replacing a shorter figure.
- ChangedPsilocin clearance is now described the same way everywhere: mainly glucuronidation and conversion to 4-HIAA, with MAO-A, CYP2D6 and CYP3A4 involved in lab studies. Some CYP3A4 inhibitor entries now say psilocin levels could in theory rise.
- ChangedEvidence codes no longer list "mechanism only" or "general references" on entries that have human data with psilocybin or another psychedelic.
- Added85 new entries, including isoniazid, safinamide, carbidopa-levodopa, clarithromycin, rifampin, azole antifungals, antiarrhythmics, more opioids and anticonvulsants, migraine medicines, blood pressure medicines, Claritin-D, codeine cough syrup, grapefruit juice, lithium orotate and several novel psychoactive substances.
- AddedNew search groups: tricyclic antidepressants, migraine, seizure, muscle relaxants, blood thinners, diabetes, antibiotics, antifungals, heart rhythm, Parkinson's and opioid blockers.
- ChangedContraindication levels now appear only where a cited clinical source states a contraindication or caution. Antipsychotics and phenothiazine anti-nausea medicines now show none listed clinically; their Colorado rule status is unchanged. Lithium and several MAO inhibitors now show relative.
- ChangedNew human data: midazolam given with psilocybin (small study), buprenorphine (two people), duloxetine and vortioxetine (case report), paroxetine with LSD. A study's group result now counts as data for a medication only when the study names that medication.
- ChangedWarning flags were checked against each medication's own FDA label; 66 missing flags were added (for example seizures, low sodium and suicidality warnings on antidepressants, and serotonin and low blood pressure warnings on opioids).
- ChangedThe two "no psilocybin data" evidence codes (mechanism only, general references) are merged into one: No psilocybin data. Entry text still says whether it rests on how the medication works or on its label.
- ChangedPlain-language rewrite of every entry's summary and detail text, with the same facts and sources. Entries without psilocybin data now say whether they are based on related drugs, on how the medication works, or on its label. Contraindication: only medications whose own label contraindicates a class that includes psilocybin are marked; other cautions appear as flags and text.
v2026.10.03c, 2026-10-03
- AddedFour new flags: psychiatric reactions, opioid, opioid blocker, and speeds up drug metabolism.
- Changed31 entries updated after a full review against current product labels, including antiseizure medicines, opioids, MAO inhibitors, antipsychotics, stimulants and several heart medicines. Flags now match label warnings, and entries state where stopping a medicine carries risk.
- ChangedEntries now present information only. Wording that told readers what to do, or who decides, has been removed; requirements appear only where a law or rule states them.
- ChangedAbout 220 more entries checked against current product labels and reference works: flags added where the source states a warning, and wording corrected where it overstated or misdescribed an interaction.
- AddedNew entries: prescription CBD (Epidiolex), cyclosporine eye drops, topical minoxidil, tacrolimus ointment, Excedrin (acetaminophen, aspirin and caffeine), NyQuil (acetaminophen, dextromethorphan and doxylamine), Advil PM / Motrin PM (ibuprofen and diphenhydramine), and Treximet (sumatriptan and naproxen).
- ChangedCondition and state-rule information corrected on about 100 entries, including Oregon's psychosis rule shown consistently for antipsychotics; brand, availability and half-life details updated on about 50 more.
- AddedFlags can now be marked "possible" when the source describes the effect as small, seen only in laboratory or animal studies, or theoretical (for example garlic and blood pressure, lemon balm and sedation).
- ChangedCondition rules now show what each Colorado licence type requires: Clinical Facilitators (2.5(A)(2)), Facilitators without the clinical licence (6.16(F)(2)(a)), and all licensees (6.16(F)(1)).
- ChangedNon-prescribed substances such as MDMA, cocaine and illicit opioids are no longer listed as a relative contraindication, since the literature does not address their combination with psilocybin; their own risks remain in each entry.
- AddedNew entry: dimenhydrinate (Dramamine Original).
- ChangedFlags added from product labels: carbamazepine (speeds up drug metabolism, withdrawal on stopping, psychiatric reactions, sedation, anticholinergic, sodium shifts); naltrexone and olanzapine-samidorphan (opioid blocker); speeds-up-drug-metabolism flag on modafinil, armodafinil, topiramate, phentermine-topiramate, clobazam, perampanel and dexamethasone.
- ChangedHalf-life notes now show reader information only (forms, metabolites, dosing context); the disclaimer matches the site's information-only wording.
- ChangedFindings from the earlier expert-panel review applied to 124 entries: flags added from product labels (for example clozapine, mirtazapine, lithium, tianeptine, timolol, hydroxychloroquine), wording corrected where it overstated an effect or misattributed it, and search names tidied.
- ChangedFlags and sources filled in where earlier checks found gaps or could not read a page: for example chlorpromazine and cocaine (QT), caffeine (withdrawal), heroin and kratom (opioid), DMT (blood pressure and heart rate), paliperidone and risperidone (seizures); several herbal effects added as "possible" (ginseng, licorice, passionflower, rhodiola).
- AddedNew flag: liver injury, on entries whose label or LiverTox record describes liver injury ("possible" where the evidence is limited).
- ChangedFamotidine now shows possible QT, seizure and psychiatric-reaction flags, limited to older adults and people with kidney impairment; mianserin, adalimumab, azithromycin, phenylephrine and others updated from sources that earlier could not be reached; unsupported statements removed from about a dozen entries, including NAD+ injections.
- AddedNew FDA status: "Over the counter under an FDA monograph", for products sold under FDA's general over-the-counter rules rather than an individual approval (for example psyllium, docusate, sodium bicarbonate and NyQuil). Entries that combine approved and monograph products say so in their status note.
v2026.10.03b, 2026-10-03
- AddedHalf-lives for most entries, each with its source; entries now say when a half-life does not apply or could not be found.
- ChangedThe evidence label "Standard practice" is now "No psilocybin data", meaning the entry is based on general references such as the product label.
- AddedNew entry: specialized pro-resolving mediators (SPM supplements). Psilocybin entry now shows psilocin half-life from a published pharmacokinetic study.
- ChangedXylazine and medetomidine now have separate entries.
- ChangedDexmedetomidine and nitroglycerin entries now cover all US forms; brexanolone is marked as withdrawn.
v2026.10.03, 2026-10-03
- AddedEvery entry now says what the medicine or substance is, its FDA approval status, its FDA-approved uses (from the FDA label) and common off-label uses, each with a source.
v2026.10.02, 2026-10-02
- AddedFirst public release: 561 medications and substances in five groups: psychotropics, general prescriptions, supplements and over-the-counter products, other substances, and peptides and related injectables.
- AddedPeptides and related injectables (including retatrutide, tesamorelin, BPC-157 and semaglutide combinations), 25 supplements and herbal products (including kanna, phenibut and Amanita muscaria products), cannabis, and common recreational and illicit substances.
- AddedOrforglipron (Foundayo) and insulin glargine–lixisenatide (Soliqua).
- EvidenceEvery entry now states whether published human data exist on combining it with psilocybin: human studies, case reports or surveys only, data from another psychedelic only, or none known. Most entries are in the last group.
- EvidenceMAO inhibitor entries rewritten around the available human data; blood pressure is the observed signal and serotonin toxicity remains theoretical.
- EvidenceLSD studies with antidepressants added and marked as data from another psychedelic, not psilocybin.
- EvidenceTrazodone: a published case in which nightly trazodone left no psychedelic effects from a 25 mg psilocybin dose.
- FlagsEvery pharmacologic flag (serotonergic, blood pressure, seizure threshold, gastric emptying and others) is backed by a public source. 5-HT2A-blocking flags were checked against receptor-binding databases.
- FlagsNew flag: dissociative (NMDA antagonist), applied to dextromethorphan products, ketamine, esketamine, PCP and nitrous oxide. Each flag now has a plain-language definition; definitions that state a fact about how psilocin is cleared carry a citation.
- SourcesEvery entry carries at least one citation; most link to the current FDA label on DailyMed.
- Half-livesHalf-lives checked against FDA labels, or the official label in the UK, EU or Canada for drugs not sold in the US. Values not confirmed on a label are not shown.
- Half-livesLabel half-lives added for all GLP-1 medications and for lamotrigine, including how other drugs change lamotrigine’s half-life.
- ColoradoColorado rule summaries checked against the official 4 CCR 755-1 text. Each entry shows whether a Colorado provision names the medication or its class.
- OregonOregon added (OAR 333-333-5050 and the Client Information Form), including the 30-day lithium provision.
- New MexicoNew Mexico added as pending. The proposed Medical Psilocybin Program rules name no medication so far.
- SearchSearch covers brand names, common misspellings, salt and dose suffixes, and street names. Plain-language group terms such as “SSRI”, “benzo”, “the pill”, “antidepressant”, “pain reliever” and “blood pressure medication” show the medicines in that group.
- FixedDuplicate entries merged, brand fields cleaned, and ibuprofen and naproxen split into separate entries.
- AddedAspirin and hydromorphone (Dilaudid).
- Added80 more entries from a coverage check against the most-prescribed US drugs, common vitamins and sports supplements, and substances tracked by the DEA, including blood-pressure medicines, QT-prolonging antibiotics, loperamide, codeine, pre-workout stimulants (synephrine, DMAA/DMHA), vitamins, nitazenes, xylazine, 7-OH, bath salts, MDA, LSD analogs, 4-AcO-DMT, NBOMes and 5-MeO-DMT as its own entry.
- Fixed"Vitamin K" no longer matches ketamine; duplicate aspirin entries merged; over-the-counter medicines grouped consistently; several entries moved to the right group; brand names cleaned and common brands added.
- EvidenceEstrogen-containing hormone therapy and contraceptives now note that estradiol increases an enzyme that clears psilocin, so psilocybin metabolism could in theory change; this has not been measured.
- New MexicoThe public hearing on the proposed rules was held on October 2, 2026. The rule has not been adopted; entries stay pending until it is published in the New Mexico Register.
- AddedEvery entry now has a one-sentence plain-language summary of its interaction text.